Voyager Therapeutics, Inc. · Brief

Next report

9 days

Nov 9 · before openest.Q3 FY26

Earnings

Expected move

No implied move.

Implied vs realized

8 reportsHistory

0 of 7≥ implied

avg implied: ±40.0%
avg realized: ±2.6%

Nov 12 '24±10.9%▼−2.05%×0.19

Mar 11 '25±27.2%▲+2.27%×0.08

May 6 '25±45.5%▲+0.92%×0.02

Aug 6 '25±41.6%▼−5.29%×0.13

Nov 10 '25±71.8%▲+0.71%×0.01

Q1 FY26—▲+21.65%—

May 7 '26±32.6%▲+2.27%×0.07

Q2 FY26±50.5%▲+4.47%×0.09

quarterimplied−75%0+75%realized×

Q2 FY26±50.5%▲+4.47%×0.09

May '26±32.6%▲+2.27%×0.07

Q1 FY26—▲+21.65%—

Nov '25±71.8%▲+0.71%×0.01

Aug '25±41.6%▼−5.29%×0.13

May '25±45.5%▲+0.92%×0.02

2 older reports

Mar '25±27.2%▲+2.27%×0.08

Nov '24±10.9%▼−2.05%×0.19

Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Bull & bear

Nov 9 report · est.

Bull2

+6.85%increase in shares held by the ten largest reporting managers last quarter13F · Jun 30 '26

136managers reporting a position in the latest quarterly filings13F · Jun 30 '26

Bear2

11 of 25largest reporting managers reducing their stake in the latest quarter13F · Jun 30 '26

19managers whose positions together make up four fifths of reported value13F · Jun 30 '26

AI captions · Sep 16 '26once per report · top 2 per case

Linked exposure

VYGR report session

Customers 1

NBIXNeurocrine Biosciences×0.16

× = co-movement · max 500dSource: SEC filings · market data

Latest changes

30 daysAll changes

Oct 28impliedImplied move: ±24.3% into Nov 9 earnings (Oct 28 close).Source

Your note

privateThesis 0 · Decisions 0 · Observations 0

No thesis.